
"We believed that with the clinical trial, Katie had the best chance of recovery. Without these trials, amazing new treatments may never be found."
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at fosaprepitant [FOS-a-PRE-pi-tant] to help stop sickness in children and young people who are having chemotherapy. This drug is also known as MK 517 or Ivemend.
This trial is for children and young people under the age of 12. We use the term ’you’ in this summary, but if you are a parent, we are referring to your child.
Chemotherapy can make you feel sick or be sick. Doctors have a number of anti sickness drugs to help control or prevent this. These work, but researchers are always looking for better treatments.
Fosaprepitant is an anti sickness drug that is approved for use in adults. Researchers want to find out if it can help prevent sickness in children and young people who are having chemotherapy.
The aims of this trial are to find out
You may be able to enter this trial if you
You cannot enter this trial if you
This is an international phase 2 trial. The trial team need 60 children and young people from different countries around the world to join.
Everyone taking part will have fosaprepitant.
You have the fosaprepitant and ondansetron as an injection into your central line. You have them before your chemotherapy.
You have a diary to record any medication you take and how many times you feel sick or are sick. You fill this in for 5 days after treatment.
For some of the people taking part, the researchers will ask to take some blood samples. This is to find out how much fosaprepitant the body absorbs, what happens to it in the body and how the body gets rid of it.
The researchers will ask to take 2 swabs form the inside of your mouth. They will use these to learn more about cancer and its treatment. You don’t have to agree to this if you don’t want. You can still take part in the trial.
You see the doctor to have some tests before taking part in this trial. These tests include
In the 1st part you see the doctor 5 times in 45 days. You may also need to stay in hospital for 1 or 2 nights. Your doctor will talk to you about this.
The most common side effects of fosaprepitant include
The most common side effects of ondansetron are
Your doctor will discuss the side effects with you before you agree to take part in this trial.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Barry Pizer
Merck, Sharp & Dohme
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"We believed that with the clinical trial, Katie had the best chance of recovery. Without these trials, amazing new treatments may never be found."